“With the passing of the 20,000 patient milestone and with more than 98 percent of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement,” Steven Ek, COO of Arthrosurface, said in the release.
The Arthrosurface inlay resurfacing technology was developed to treat younger and more active patients, such as baby boomers, and is cleared for use in the knee, shoulder, hip and toe.
Read the Arthrosurface release on the 20,000 patient milestone.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
